Pharmaceutical - Production, Respiratory and Pulmonary


Popular Filters

Boehringer Ingelheim invests 100 million euros to expanded Respimat production, as it's launched in UK

Boehringer Ingelheim invests 100 million euros to expanded Respimat production, as it's launched in UK


German family-owned pharma major Boehringer Ingelheim is investing more than 100 million euros ($127…

Boehringer IngelheimGermanyMarkets & MarketingPharmaceuticalProductionRespimatRespiratory and PulmonarySpiriva RespimatUK

Akrikhin expands deal with Merck & Co


Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member


German family-owned drug major Boehringer Ingelheim said today (May 17) that it is updating health care…

Boehringer IngelheimCombivent RespimatManagementPharmaceuticalProductionRespiratory and Pulmonary

Vectura sets up JV, Kinnovata, for new respiratory business in China


UK-based developer of inhaled therapies Vectura (LSE: VEC) saw its shares rise 4.8% to 96.93 pence in…

Asia-PacificMergers & AcquisitionsPharmaceuticalProductionRespiratory and PulmonaryTianjin KingYorkTianjin Kinnovata PharmaVecturaZendex Bio Strategy

Merck & Co opens new $120 million manufacturing plant in China


US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Boehringer Ingelheim highlights robust respiratory R&D pipeline; announces investment


At its 3rd International Research & Development press conference, family-owned German drug major Boehringer…

afatinibBoehringer IngelheimnintedanibolodaterolOncologyPharmaceuticalProductionResearchRespimatRespiratory and Pulmonary

Back to top